Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 14, 2000, Pages 1519-1522

  DeLong, Mitchell A ^a   Amburgey, Jack ^a   Taylor, Cynthia ^a   Wos, John A ^a   Soper, David L ^a   Wang, Yili ^a   Hicks, Renee ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR;

ANIMAL CELL; ARTICLE; CHEMICAL BOND; CHEMICAL MODIFICATION; HUMAN; IN VITRO STUDY; NONHUMAN; RECEPTOR BINDING; STRUCTURE ANALYSIS; SYNTHESIS;

HUMANS; KINETICS; MODELS, STRUCTURAL; MOLECULAR CONFORMATION; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034679747     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00273-0     Document Type: Article

References (18)

1. (a) Rudolph, M. I.; Reinicke, K.; Cruz, M. A.; Gallardo, V.; Gonzalez, C.; Bardisa, L. Br. J. Obsetet. Gynaecol. 1993, 100, 1125.
2. (b) Crankshaw, D. J.; Dyal, R. Can. J. Physiol. Pharmacol. 1994, 72, 870.
3. (c) Crankshaw, D. J.; Dyal, R. J. Clin. Endrocrinol. Metab. 1992, 75, 1027.
4. (d) Garcia-Villar, R.; Marnet, P. G.; Laurentie, M. P.; Toutain, P. L. Am. J. Vet. Res. 1985, 46, 841.
5. (e) Featherstone, R. L.; Robinson, C.; Holgate, S. T.; Church, M. K. Naunyn-Schiedebergs Arc. Pharmacol. 1990, 341, 439.
6. (f) McKenniff, M. G.; Norman, P.; Cuthbert, N. J.; Gardiner, P. J. Br. J. Pharmacol. 1991, 104, 585.
7. (a) Coleman, R. A.; Humphrey, P. P. A.; Kennedy, I.; Lumley, P. Trends Pharmacol. Sci. 1984 5, 303.
8. (b) Coleman, R. A.; Smith, W. L. Narumiya, S. Pharmacol. Rev. 1994, 46, 205.
9. Toris C.B., Camras C.B., Yablonski M.E. Ophthalmology. 100:1993;1297.
10. Our compilation was published: Hopfinger, A. J. Wang, S.; Tokarski, J. S.; Jin, B. Q.; Albuquerque, M.; Madhav, P. J.; Duraiswami, C. J. Am. Chem. Soc. 1997, 119, 10509.
11. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. Cell. 83:1995;813.
12. (a) Hartke, J. R.; Jankowsky, M. L.; deLong, M. A.; Soehner, M. E.; Jee, W. S. S.; Lundy, M. W J. Bone Min. Res., 1999, 14, S207.
13. (b) deLong, M. A.; Miley, C. J.; Amburgey, J. S.; Roof, S. L.; Pierce, S.; Lundy, M. W. Abstracts Of Papers, Part 2, 213th National Meeting of the American Chemical Society, San Francisco, CA; American Chemical Society: Washington, DC, 1997, Abstract 135-MEDI.
14. (c) Soper, D. L.; Brann, M.; Amburgey, J.; Miley, C.; Wos, J.; Wang, Y.; Hartke, J.; deLong, M. A. Abstracts Of Papers, Part 1, 215th National Meeting of the American Chemical Society, Dallas, TX; ACS: Washington, DC, 1998, Abstract A050-MEDI.
15. 50 shown is after timed hydrolysis of galactosidase pseudsubstrate. For details: Messier, T.; Dorman, C.M.; Brauner, H.; Eubanks, D.; Brann, M. R. Pharmacol. Toxicol. 1995, 76, 308.
16. 3H]U46619 (hTP) in membrane preparations isolated from CHO-KI cells stably transfected with the receptor. The radiolabel (5 nM) membrane and test compound were incubated together 1h; plates harvested and DPM's counted.
17. Dukes M., Russell W., Walpole A.L. Nature. 250:1974;330.
18. No, K.; Resul, B.; Nilsson, B.; Thor, M.; Liljebris, C.; Selen, G.; Sternschantz, J. XIV International Symposium on Medicinal Chemistry, Maastricht, Netherlands, 1996, Abstract #2.29.